Applied BioMath
Corporate Fact Sheet

About | Systems pharmacology and mechanistic modeling, simulation, and analysis to accelerate and de-risk drug R&D

We support cutting-edge therapies with a variety of clients*

- AbbVie
- Alexion
- Biogen
- Checkpoint
- Codiak
- Compass
- CytomX
- Gritstone
- Ironwood
- Jounce
- KSQ
- Northern Biologics
- Novartis
- Obsidian
- OncoMyx
- Pandion
- Pfizer
- Revitope
- Sanofi
- Shire
- Syntimmune
- Takeda
- Tusk
- Verseau
- Xencor
- Xilio
- Zymeworks

>80%	130+	>50	$4.7M
Repeat business rate	Projects	Clients	NIH and FDA grant funding

Areas of impact for systems pharmacology throughout drug R&D

| Early Feasibility	Lead Generation	Clinical Candidate Selection	IND	Early Stage Clinical	Late Stage Clinical
Therapeutic Concept	Optimal Properties	Competitor Differentiation	Species Translation	Indication	RP2D
	Experimental Design and Prioritization	In-licensing Risks		Indication Hopping	Dose Expansion
	Therapeutic Index	Early Dose Predictions	FIH Dose/Regimen		Patient Stratification
					BLA

* This list only includes clients in the public domain.

Our interdisciplinary team has a breadth of pharma and biotech experience

- Biochemistry
- Chemical Engineering
- Applied Math
- Biology
- Computational Biology
- Biomedical Engineering

80+ years — Combined pharma & biotech experience

4 Patents

20+ Posters and papers

75% Team members holding a scientific doctorate

37 Employees

Our modeling services include, but are not limited to the following

- Semi-mechanistic PK/PD
- Quantitative Systems Pharmacology (QSP)
- Quantitative Systems Toxicology (QST)
- Pre-IND and IND writing
- PK/PD analysis

- Bioinformatics
- Population PK/PD
- Biomarker data analysis
- Pathway model development
- Toxicokinetic data analysis

Our experience spans many therapeutic areas and drug concepts

Therapeutic Areas	Drug Concepts	

• Oncology
• Immuno-oncology
• Inflammation & Immunology
• Infectious Disease
• Respiratory/ Cardiovascular
• CNS/ Alzheimer's Disease
• Metabolic
• Pain
• Rare and Orphan
• Ocular Disease
	• Large Molecules
	  • Monoclonal Antibody
	  • Antibody Drug Conjugate
	  • Bi/Tri-specific
	  • Tissue Targeting Biologics
	  • Peptides
	  • Fusion Protein Multi-specifics
	  • Multi-specifics vs. Fixed-Dose Combination
	  • Blood-brain barrier (multi-specifics)
	  • Pro biologics
	  • Prodrug
		• Cell Therapies
		• Gene Therapies
		• Small Molecules
		  • Irreversible binders
		  • Proteostasis
		• Combination Therapies
		• Lipid Nanoparticle
		• RNA / RNAi Therapies